You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePipotiazine
Accession NumberDB01621
TypeSmall Molecule
GroupsApproved
DescriptionPipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
Structure
Thumb
Synonyms
Piportil
Pipothiazine
Pipotiazina
Pipotiazinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Piportil L4solution50 mgintramuscularSanofi Aventis Canada Inc1980-12-31Not applicableCanada
Piportil L4solution25 mgintramuscularSanofi Aventis Canada Inc1980-12-312016-08-17Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pipotiazine palmitate
ThumbNot applicableDBSALT001196
Categories
UNIIL903J9JPYV
CAS number39860-99-6
WeightAverage: 475.667
Monoisotopic: 475.196333317
Chemical FormulaC24H33N3O3S2
InChI KeyInChIKey=JOMHSQGEWSNUKU-UHFFFAOYSA-N
InChI
InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3
IUPAC Name
10-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl}-N,N-dimethyl-10H-phenothiazine-2-sulfonamide
SMILES
CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenesulfonamide
  • Benzenoid
  • Piperidine
  • Para-thiazine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the maintenance treatment of chronic non-agitated schizophrenic patients.
PharmacodynamicsPipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It reduces activity of dopamine receptors in the limbic system. Its 5-HT antagonism helps normalize dopamine activity in the cortical regions.
Mechanism of actionPipotiazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9896
Blood Brain Barrier+0.9461
Caco-2 permeable-0.6479
P-glycoprotein substrateSubstrate0.7257
P-glycoprotein inhibitor IInhibitor0.774
P-glycoprotein inhibitor IINon-inhibitor0.5492
Renal organic cation transporterNon-inhibitor0.6426
CYP450 2C9 substrateNon-substrate0.6896
CYP450 2D6 substrateNon-substrate0.747
CYP450 3A4 substrateSubstrate0.5077
CYP450 1A2 substrateNon-inhibitor0.8021
CYP450 2C9 inhibitorNon-inhibitor0.8585
CYP450 2D6 inhibitorNon-inhibitor0.764
CYP450 2C19 inhibitorNon-inhibitor0.6829
CYP450 3A4 inhibitorInhibitor0.5623
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6904
Ames testNon AMES toxic0.6482
CarcinogenicityNon-carcinogens0.7615
BiodegradationNot ready biodegradable0.9723
Rat acute toxicity2.5406 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8642
hERG inhibition (predictor II)Inhibitor0.5429
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Solutionintramuscular25 mg
Solutionintramuscular50 mg
Prices
Unit descriptionCostUnit
Piportil L4 50 mg/ml56.19USD ml
Piportil L4 25 mg/ml17.45USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP3.94ALOGPS
logP3.13ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)17.09ChemAxon
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.09 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity134.12 m3·mol-1ChemAxon
Polarizability53.17 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetaminePipotiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetaminePipotiazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pipotiazine.
AbirateroneThe serum concentration of Pipotiazine can be increased when it is combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Pipotiazine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pipotiazine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pipotiazine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pipotiazine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Pipotiazine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pipotiazine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Pipotiazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pipotiazine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pipotiazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pipotiazine.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pipotiazine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pipotiazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipotiazine.
AmiodaroneThe metabolism of Pipotiazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pipotiazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipotiazine.
AmoxapineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pipotiazine.
AmphetaminePipotiazine may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Pipotiazine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipotiazine.
ArmodafinilThe metabolism of Pipotiazine can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Pipotiazine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pipotiazine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pipotiazine.
AtazanavirThe metabolism of Pipotiazine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Pipotiazine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Pipotiazine.
AzelastinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pipotiazine.
AzithromycinThe metabolism of Pipotiazine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pipotiazine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pipotiazine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pipotiazine.
BenzphetaminePipotiazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pipotiazine.
BetaxololThe metabolism of Pipotiazine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Pipotiazine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Pipotiazine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Pipotiazine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Pipotiazine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
BrimonidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipotiazine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipotiazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pipotiazine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pipotiazine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Pipotiazine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipotiazine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pipotiazine.
BupropionThe metabolism of Pipotiazine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipotiazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipotiazine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Pipotiazine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pipotiazine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Pipotiazine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pipotiazine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipotiazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pipotiazine.
CaffeineThe metabolism of Pipotiazine can be decreased when combined with Caffeine.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pipotiazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pipotiazine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pipotiazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pipotiazine.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pipotiazine.
CelecoxibThe metabolism of Pipotiazine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Pipotiazine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pipotiazine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pipotiazine.
ChloramphenicolThe metabolism of Pipotiazine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pipotiazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pipotiazine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pipotiazine.
ChloroquineThe metabolism of Pipotiazine can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipotiazine.
ChlorphenterminePipotiazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe metabolism of Pipotiazine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pipotiazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipotiazine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pipotiazine.
CholecalciferolThe metabolism of Pipotiazine can be decreased when combined with Cholecalciferol.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pipotiazine.
CimetidineThe metabolism of Pipotiazine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Pipotiazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pipotiazine.
CitalopramThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Citalopram.
ClarithromycinThe metabolism of Pipotiazine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Pipotiazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pipotiazine.
ClobazamThe metabolism of Pipotiazine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pipotiazine.
ClomipramineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pipotiazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pipotiazine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipotiazine.
ClotrimazoleThe metabolism of Pipotiazine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Pipotiazine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clozapine.
CobicistatThe serum concentration of Pipotiazine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pipotiazine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pipotiazine.
ConivaptanThe serum concentration of Pipotiazine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Pipotiazine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pipotiazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipotiazine.
CyclosporineThe metabolism of Pipotiazine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pipotiazine.
Cyproterone acetateThe serum concentration of Pipotiazine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Pipotiazine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pipotiazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipotiazine.
DapoxetineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dapoxetine.
DarifenacinThe metabolism of Pipotiazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Pipotiazine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Pipotiazine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Pipotiazine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Pipotiazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Pipotiazine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipotiazine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Pipotiazine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipotiazine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pipotiazine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Pipotiazine.
DexamethasoneThe serum concentration of Pipotiazine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pipotiazine.
DextroamphetaminePipotiazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pipotiazine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pipotiazine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pipotiazine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pipotiazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pipotiazine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pipotiazine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipotiazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipotiazine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pipotiazine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipotiazine.
DiltiazemThe metabolism of Pipotiazine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipotiazine.
DiphenhydramineThe metabolism of Pipotiazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipotiazine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Pipotiazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Pipotiazine.
DoxycyclineThe metabolism of Pipotiazine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
DoxylamineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pipotiazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
DronedaroneThe metabolism of Pipotiazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Pipotiazine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pipotiazine.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pipotiazine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pipotiazine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipotiazine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pipotiazine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Pipotiazine.
EfavirenzThe serum concentration of Pipotiazine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipotiazine.
EliglustatThe metabolism of Pipotiazine can be decreased when combined with Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pipotiazine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pipotiazine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pipotiazine.
EnzalutamideThe serum concentration of Pipotiazine can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipotiazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipotiazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pipotiazine.
ErythromycinThe metabolism of Pipotiazine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Pipotiazine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Pipotiazine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pipotiazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipotiazine.
EthanolPipotiazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pipotiazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipotiazine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipotiazine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pipotiazine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipotiazine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pipotiazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pipotiazine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Pipotiazine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pipotiazine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pipotiazine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipotiazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pipotiazine.
EtravirineThe serum concentration of Pipotiazine can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Pipotiazine.
EzogabineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pipotiazine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pipotiazine.
FenfluramineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipotiazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pipotiazine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pipotiazine.
FlibanserinThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flibanserin.
FluconazoleThe metabolism of Pipotiazine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pipotiazine.
FlunarizineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pipotiazine.
FluoxetineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipotiazine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipotiazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipotiazine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipotiazine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pipotiazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluvoxamine.
FosamprenavirThe metabolism of Pipotiazine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pipotiazine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Pipotiazine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pipotiazine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Pipotiazine.
Fusidic AcidThe serum concentration of Pipotiazine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipotiazine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pipotiazine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pipotiazine.
GemfibrozilThe metabolism of Pipotiazine can be decreased when combined with Gemfibrozil.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pipotiazine.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Pipotiazine.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Pipotiazine.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Pipotiazine.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pipotiazine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pipotiazine.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Pipotiazine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pipotiazine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pipotiazine.
HaloperidolThe metabolism of Pipotiazine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pipotiazine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pipotiazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pipotiazine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pipotiazine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipotiazine.
Hydroxyamphetamine hydrobromidePipotiazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Pipotiazine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Iloperidone.
ImatinibThe metabolism of Pipotiazine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Pipotiazine.
IndalpineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Indalpine.
IndinavirThe metabolism of Pipotiazine can be decreased when combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Pipotiazine.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Pipotiazine.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Pipotiazine.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Pipotiazine.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Pipotiazine.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pipotiazine.
IsavuconazoniumThe metabolism of Pipotiazine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipotiazine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pipotiazine.
IsoniazidThe metabolism of Pipotiazine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Pipotiazine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Pipotiazine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Pipotiazine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipotiazine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pipotiazine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pipotiazine.
KetoconazoleThe metabolism of Pipotiazine can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipotiazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pipotiazine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pipotiazine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Pipotiazine.
LevocetirizineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pipotiazine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pipotiazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipotiazine.
LidocaineThe metabolism of Pipotiazine can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Pipotiazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Pipotiazine.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Pipotiazine.
LisdexamfetaminePipotiazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Pipotiazine.
LithiumThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pipotiazine.
LopinavirThe metabolism of Pipotiazine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pipotiazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pipotiazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pipotiazine.
LovastatinThe metabolism of Pipotiazine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipotiazine.
Lu AA21004The risk or severity of adverse effects can be increased when Pipotiazine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Pipotiazine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pipotiazine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Pipotiazine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipotiazine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pipotiazine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Pipotiazine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pipotiazine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Pipotiazine.
MephenterminePipotiazine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipotiazine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipotiazine.
MequitazinePipotiazine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipotiazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipotiazine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pipotiazine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pipotiazine.
MethamphetaminePipotiazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pipotiazine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pipotiazine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipotiazine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipotiazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Pipotiazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pipotiazine.
MethsuximideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pipotiazine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipotiazine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pipotiazine.
MetoprololThe metabolism of Pipotiazine can be decreased when combined with Metoprolol.
MetyrosinePipotiazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Pipotiazine.
MexiletineThe metabolism of Pipotiazine can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipotiazine.
MifepristoneThe metabolism of Pipotiazine can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pipotiazine.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Pipotiazine.
MilnacipranThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
MirabegronThe metabolism of Pipotiazine can be decreased when combined with Mirabegron.
MirtazapinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pipotiazine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Pipotiazine.
MitotaneThe serum concentration of Pipotiazine can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pipotiazine.
ModafinilThe serum concentration of Pipotiazine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pipotiazine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pipotiazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
NabiloneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Nabilone.
NafcillinThe serum concentration of Pipotiazine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipotiazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pipotiazine.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Pipotiazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Pipotiazine.
NelfinavirThe metabolism of Pipotiazine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Pipotiazine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Pipotiazine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Pipotiazine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Pipotiazine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipotiazine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pipotiazine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Pipotiazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pipotiazine.
OlanzapineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Olanzapine.
OlaparibThe metabolism of Pipotiazine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pipotiazine.
OmeprazoleThe metabolism of Pipotiazine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipotiazine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Pipotiazine.
OrphenadrinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipotiazine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Pipotiazine.
OsimertinibThe serum concentration of Pipotiazine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipotiazine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipotiazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pipotiazine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipotiazine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipotiazine.
PalbociclibThe serum concentration of Pipotiazine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipotiazine.
PanobinostatThe metabolism of Pipotiazine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Pipotiazine can be decreased when combined with Pantoprazole.
ParaldehydePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Pipotiazine.
ParoxetineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Pipotiazine can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipotiazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pipotiazine.
PerampanelThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Pipotiazine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipotiazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipotiazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipotiazine.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Pipotiazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipotiazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Pipotiazine.
PhenterminePipotiazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pipotiazine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipotiazine.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pipotiazine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pomalidomide.
PosaconazoleThe metabolism of Pipotiazine can be decreased when combined with Posaconazole.
PramipexolePipotiazine may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Pipotiazine.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Pipotiazine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pipotiazine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pipotiazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pipotiazine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Pipotiazine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pipotiazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pipotiazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipotiazine.
PromazineThe metabolism of Pipotiazine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pipotiazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pipotiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pipotiazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Pipotiazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipotiazine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Pipotiazine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipotiazine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipotiazine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Pipotiazine.
QuinidineThe metabolism of Pipotiazine can be decreased when combined with Quinidine.
QuinineThe metabolism of Pipotiazine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pipotiazine.
RanolazineThe metabolism of Pipotiazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipotiazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipotiazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipotiazine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Pipotiazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipotiazine.
RifabutinThe metabolism of Pipotiazine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Pipotiazine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Pipotiazine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pipotiazine.
RitonavirThe metabolism of Pipotiazine can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pipotiazine.
RolapitantThe metabolism of Pipotiazine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Pipotiazine.
RopinirolePipotiazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Pipotiazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipotiazine.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pipotiazine.
RotigotinePipotiazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pipotiazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pipotiazine.
SaquinavirThe metabolism of Pipotiazine can be decreased when combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pipotiazine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipotiazine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipotiazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Pipotiazine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Pipotiazine.
SertralineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipotiazine.
SildenafilThe metabolism of Pipotiazine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Pipotiazine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pipotiazine can be increased when it is combined with Simeprevir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pipotiazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Pipotiazine.
St. John's WortThe serum concentration of Pipotiazine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine.
SulfisoxazoleThe metabolism of Pipotiazine can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pipotiazine.
SulpirideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Pipotiazine.
SuvorexantThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pipotiazine.
TasimelteonThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pipotiazine.
TelaprevirThe metabolism of Pipotiazine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Pipotiazine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipotiazine.
TenofovirThe metabolism of Pipotiazine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Pipotiazine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Pipotiazine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipotiazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pipotiazine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pipotiazine.
ThalidomidePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pipotiazine.
TheophyllineThe metabolism of Pipotiazine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipotiazine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pipotiazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pipotiazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pipotiazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipotiazine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pipotiazine.
TiclopidineThe metabolism of Pipotiazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Pipotiazine.
TipranavirThe metabolism of Pipotiazine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pipotiazine.
TocilizumabThe serum concentration of Pipotiazine can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Pipotiazine.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pipotiazine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pipotiazine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pipotiazine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipotiazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pipotiazine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipotiazine.
TrazodoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipotiazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipotiazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipotiazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pipotiazine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pipotiazine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Pipotiazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pipotiazine.
VemurafenibThe serum concentration of Pipotiazine can be increased when it is combined with Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Pipotiazine.
VerapamilThe metabolism of Pipotiazine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pipotiazine.
VilazodoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pipotiazine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Pipotiazine.
VoriconazoleThe metabolism of Pipotiazine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Pipotiazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipotiazine.
ZiconotideThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Zimelidine.
ZiprasidoneThe metabolism of Pipotiazine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Pipotiazine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipotiazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pipotiazine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pipotiazine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pipotiazine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Pipotiazine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipotiazine.
Food Interactions
  • Avoid alcohol
  • Take with food to decrease irritation

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263 ]
  4. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]
  7. Boireau A, Chambry J, Dubedat P, Farges G, Carruette AM, Zundel JL, Blanchard JC: Enhancing effect of dopamine blockers on evoked acetylcholine release in rat striatal slices: a classical D-2 antagonist response? Eur J Pharmacol. 1986 Aug 22;128(1-2):93-8. [PubMed:2875894 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438 ]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134 ]
  2. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. [PubMed:19902987 ]
  2. Bhoopathy S, Xin B, Unger SE, Karnes HT: A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes. J Pharm Biomed Anal. 2005 Apr 1;37(4):739-49. Epub 2004 Dec 30. [PubMed:15797796 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. doi: 10.1016/j.bcp.2010.06.045. Epub 2010 Jul 6. [PubMed:20615392 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. doi: 10.1016/j.bcp.2010.06.045. Epub 2010 Jul 6. [PubMed:20615392 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. doi: 10.1016/j.bcp.2010.06.045. Epub 2010 Jul 6. [PubMed:20615392 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214 ]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920 ]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 14:16 / Updated on August 17, 2016 12:23